ProCE Banner Activity

Combined Analysis of ATLAS, FLAIR, ATLAS-2M: Efficacy and Safety of Switch to LA CAB + RPV by BMI Class

Slideset Download
Across phase III/IIIb trials through Week 48, LA CAB + RPV maintained high rates of virologic suppression across dosing strategies and BMI categories; no participant with BMI ≥30 kg/m2 as only baseline risk factor met CVF criterion.

Released: November 05, 2021

Expiration: November 04, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

ViiV Healthcare